|
Dr. Gendreau is the longest serving member of the Cypress management team, having joined the company in 1994. He has 20+ years of experience in the development, clinical evaluation and commercialization of drug, biologic, medical device, and diagnostic products. Dr. Gendreau led the team that designed and managed Cypress' successful Phase III pivotal trial program and subsequent FDA submissions (1996-1999) for the Company's former rheumatoid arthritis treatment, the Prosorba column. With the change in focus of Cypress to fibromyalgia and related functional somatic syndromes, he has been responsible for the company's current clinical programs evaluating milnacipran as a pharmacological treatment for the signs and symptoms of the fibromyalgia syndrome. From 1991 to 1994, he served in various senior management roles in research, clinical development and regulatory affairs for Microprobe, Inc. of Seattle, WA, a biotechnology company developing oligonucleotide technology for diagnostic and therapeutic applications. From 1988 to 1991, Dr. Gendreau served as Vice President of research and development for Source Scientific Systems, a developer and manufacturer of OEM medical devices. From 1981 to 1988, Dr. Gendreau served as manager of world wide Health Care Technology for the Battelle Memorial Institute of Columbus, OH. At Battelle, he served as a medical technology consultant, managed scientific and clinical development programs globally, supervised reimbursement and policy analysis, and developed diagnostic products. He also concurrently while at Battelle spent five years as Principal Investigator of the "National Center for Biomedical Spectroscopy", an NIH funded center of excellence based on findings from Dr. Gendreau's doctoral research at Ohio State. Dr. Gendreau received his B.S. degree in Chemistry from Ohio University, and his M.D./Ph.D. degree in medicine and pharmacology from the Ohio State University, where he graduated summa cum laude. | 